Insights
Professional
Practice
Industry
Region
Trending Topics
Location
Type
Sort by:
Firm News 1 result
Firm News | 2 min read | 05.30.24
Crowell & Moring Honors Recipients of 25th Annual George Bailey Public Service Awards
Washington, D.C. – May 30, 2024: Crowell & Moring hosted its 25thannual George Bailey Public Service Awards ceremony. Named after the hero of the classic movie, “It’s a Wonderful Life,” these awards recognize the firm’s lawyers and staff who have made a substantial impact on the lives of others through their pro bono work.
Client Alerts 4 results
Client Alert | 2 min read | 06.27.24
As reported in earlier Client Alerts, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In response, some manufacturers withdrew their patents, and others agreed to cap certain out-of-pocket costs for their drugs, resulting in a “victory lap” of media activity from the FTC in April.
Client Alert | 4 min read | 05.07.24
The Food and Drug Administration (FDA) has published revised draft guidelines in the Federal Register on promotional labeling and advertising considerations for the biologic and biosimilar industry, updating guidance from 2020. The quick revisions emphasize the fast-changing and rapidly growing nature of this industry.
Client Alert | 4 min read | 04.29.24
Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents
As reported in an earlier Client Alert, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In the letters, the FTC indicated it is using the FDA’s regulatory dispute process to challenge the listing of these patents in the Orange Book because improperly listed patents may violate antitrust laws and impede competition.
Publications 3 results
Publication | December 2023
LexisNexisBlog Posts 12 results
Blog Post | 12.03.24
FTC Updates (November 18-29, 2024)
Crowell & Moring’s Retail & Consumer Products Law ObserverBlog Post | 09.13.24
FTC Updates (September 2-6, 2024)
Crowell & Moring’s Retail & Consumer Products Law ObserverBlog Post | 07.26.24
Crowell & Moring’s Retail & Consumer Products Law Observer